Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions
Recurrent Neuroblastoma
Interventions
DRUG

metronomic therapy

"* Propranolol 0.5 mg/kgxd p.o. day 1,~ 1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"

Trial Locations (8)

50924

Marc Hoemberg, Cologne

Unknown

Children's University Hospital, Bonn

Children's University Hospital, Essen

Children's University Hospital, Frankfurt

Children's University Hospital, Freiburg im Breisgau

Children's Hospital, Medizinische Hochschule, Hanover

Children's University Hospital, Leipzig

Dr. von Haunersches Kinderspital, München

All Listed Sponsors
lead

University of Cologne

OTHER

NCT02641314 - Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma | Biotech Hunter | Biotech Hunter